February 5, 2025 11:15 AM EST

EyePoint shares more mid-stage data for therapy trying to compete with Regeneron's Eylea

Kyle LaHucik

Senior Reporter

EyePoint Pharmaceuticals, a biotech attempting to grab a sliver of Regeneron’s share of the degenerative eye disease market, said six-month results show its drug met …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

EyePoint shares more mid-stage data for therapy trying to compete with Regeneron's Eylea

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bristol Myers, Kyowa Kirin disclose layoffs

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

Novo Nordisk is feeling the competition from compounded GLP-1s, exec says

GSK defiant against vaccine challenges, will prioritize other growth areas

With first drug now in the clinic, Alys eyes megaround for rest of pipeline

Eye­Point shares more mid-stage da­ta for ther­a­py try­ing to com­pete with Re­gen­eron's Eylea

Senior Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

EyePoint shares more mid-stage data for therapy trying to compete with Regeneron's Eylea